Key result
Periprocedural acetylsalicylic acid and unfractionated heparin are being evaluated for their effect on 90-day functional outcome in patients undergoing endovascular treatment for acute ischemic stroke.
Why the study?
It is unknown whether periprocedural antithrombotic medication with acetylsalicylic acid or unfractionated heparin improves functional outcome in patients undergoing endovascular treatment for acute ischemic stroke.
Does periprocedural acetylsalicylic acid and/or unfractionated heparin improve functional outcome in adult patients with acute ischemic stroke undergoing endovascular treatment?
RCT (n=1,500)
Open-label, blinded end-point (PROBE)
2x3 factorial
Yes
Does periprocedural acetylsalicylic acid and/or unfractionated heparin improve functional outcome in adult patients with acute ischemic stroke undergoing endovascular treatment?
Answers are grounded in this paper and cite their sources.
The MR CLEAN-MED trial is designed to evaluate whether adjunctive periprocedural antithrombotic medication (ASA and/or UFH) improves functional outcomes in patients undergoing endovascular treatment for acute ischemic stroke.
BACKGROUND: Despite evidence of a quite large beneficial effect of endovascular treatment (EVT) for ischemic stroke caused by anterior circulation large vessel occlusion, many patients do not recover even after complete recanalization. To some extent, this may be attributable to incomplete microvascular reperfusion, which can possibly be improved by antiplatelet agents and heparin. It is unknown whether periprocedural antithrombotic medication in patients treated with EVT improves functional outcome. The aim of this study is to assess the effect of acetylsalicylic acid (ASA) and unfractionated heparin (UFH), alone, or in combination, given to patients with an ischemic stroke caused by an intracranial large vessel occlusion in the anterior circulation during EVT. METHODS: MR CLEAN-MED is a multicenter phase III trial with a prospective, 2 × 3 factorial randomized, open label, blinded end-point (PROBE) design, which aims to enroll 1500 patients. The trial is designed to evaluate the effect of intravenous ASA (300 mg), UFH (low or moderate dose), both or neither as adjunctive therapy to EVT. We enroll adult patients with a clinical diagnosis of stroke (NIHSS ≥ 2) and with a confirmed intracranial large vessel occlusion in the anterior circulation on CTA or MRA, when EVT within 6 h from symptom onset is indicated and possible. The primary outcome is the score on the modified Rankin Scale (mRS) at 90 days. Treatment effect on the mRS will be estimated with ordinal logistic regression analysis, with adjustment for main prognostic variables. Secondary outcomes include stroke severity measured with the NIHSS at 24 h and at 5-7 days, follow-up infarct volume, symptomatic intracranial hemorrhage (sICH), and mortality. DISCUSSION: Clinical equipoise exists whether antithrombotic medication should be administered during EVT for a large vessel occlusion, as ASA and/or UFH may improve functional outcome, but might also lead to an increased risk of sICH. When one or both of the study treatments show the anticipated effect on outcome, we will be able to improve outcome of patients treated with EVT by 5%. This amounts to more than 50 patients annually in the Netherlands, more than 1800 in Europe, and more than 1300 in the USA. TRIAL REGISTRATION: ISRCT, ISRCTN76741621 . Dec 6, 2017.
No takes yet. Share an insight, caveat, or question.
Chalos et al. (2020) conducted an RCT in Acute ischemic stroke (n=1,500). Acetylsalicylic acid (ASA) and/or unfractionated heparin (UFH) vs. No ASA and no UFH was evaluated on Modified Rankin Scale (mRS) score at 90 days. Periprocedural acetylsalicylic acid and unfractionated heparin are being evaluated for their effect on 90-day functional outcome in patients undergoing endovascular treatment for acute ischemic stroke.
Synapse has enriched 10 related papers. Consider them for comparative context: